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Use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of gastric or oesophageal
adenocarcinomas. We examined the association between self-reported use of aspirin or non-aspirin NSAIDs in the earlier 12 months
and gastric non-cardia (N¼182), gastric cardia (N¼178), and oesophageal adenocarcinomas (N¼228) in a prospective cohort
(N¼311115) followed for 7 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) come from Cox models adjusted for
potential confounders. Use of any aspirin (HR, 95% CI: 0.64, 0.47–0.86) or other NSAIDs (0.68, 0.51–0.92) was associated with a
significantly lower risk of gastric non-cardia adenocarcinoma. Neither aspirin (0.86, 0.61–1.20) nor other NSAIDs (0.91, 0.67–1.22)
had a significant association with gastric cardia cancer. We found no significant association between using aspirin (1.00, 0.73–1.37) or
other NSAIDs (0.90, 69–1.17) and oesophageal adenocarcinoma. We also performed a meta-analysis of the association between
the use of NSAIDs and risk of gastric and oesophageal adenocarcinoma. In this analysis, aspirin use was inversely associated with both
gastric and oesophageal adenocarcinomas, with summary odds ratios (95% CI) for non-cardia, cardia, and oesophageal
adenocarcinomas of 0.64 (0.52–0.80), 0.82 (0.65–1.04), and 0.64 (0.52–0.79), respectively. The corresponding numbers for other
NSAIDs were 0.68 (0.57–0.81), 0.80 (0.67–0.95), and 0.65 (0.50–0.85), respectively.
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Aspirin may prevent heart disease (Hennekens and Schneider,
2008) and colon cancer (Dube ´ et al, 2007), but the US Preventive
Services Task Force does not endorse an aspirin regimen for
primary chemoprevention of colon cancer (US Preventive
Services Task Force, 2007). Daily aspirin use carries the risk of
gastrointestinal bleeding and haemorrhagic stroke and the
expected benefits do not outweigh the risks, at least in individuals
at average risk for colorectal cancer. If additional chemopreventive
benefits at sites other than the colon could be included in the risk
benefit analysis, this calculation may change.
Worldwide, gastric cancer remains the second leading cause of
death due to cancer, with over 900000 incident cases and about
700000 deaths (Parkin et al, 2002). Although gastric cancer
incidence rates are decreasing in the United States, about 21000
incident cases occur each year (Ries and Melbert, 2007). In
contrast, oesophageal adenocarcinoma rates have increased
dramatically over the last 30 years in many Western countries,
and there are about 9000 incident cases in the United States each
year (Ries and Melbert, 2007). Both stomach and oesophageal
cancers have high fatality rates, only 24 and 16% 5-year survival
respectively, so preventive strategies are particularly important for
these cancers. Earlier studies suggest that the incidence of
adenocarcinomas of the oesophagus and stomach may be reduced
by the use of aspirin or other non-steroidal anti-inflammatory
drugs (NSAIDs) (Corley et al, 2003; Gonzalez-Perez et al, 2003;
Wang et al, 2003), but few studies have been prospective, used data
collected directly from subjects, and controlled for the many
potential confounders.
We aimed to examine the association between aspirin and non-
aspirin NSAID use and risk of oesophageal, gastric cardia, and
gastric non-cardia adenocarcinoma in the NIH-AARP Diet and
Health Study cohort, a large prospective study conducted in the
United States.
METHODS
The NIH-AARP Diet and Health Study is a large prospective cohort
study designed to investigate the association between diet and
other factors and risk of cancer and has been described in detail
previously (Schatzkin et al, 2001). Between 1995 and 1996, a
questionnaire was mailed to 3.5 million AARP members (aged
50–71 years) in eight US states (California, Florida, Georgia,
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In total, 617119 individuals returned the questionnaire. A second
mailed questionnaire (1996–1997) collected additional informa-
tion including NSAID use and 334908 individuals were available
for analysis. We excluded subjects for whom either the
baseline (N¼6959) or the follow-up questionnaire (N¼3424)
was completed by proxies, those with prevalent cancer at the
second questionnaire baseline (N¼4543), those with incomplete
information about NSAID use (N¼6353), those with total energy
intake more than twice the interquartile range from the median
(N¼2506), and those who exited on the first day of follow-up
(N¼8). The resulting cohort included 311115 participants
including 180337 men and 130778 women. The NIH-AARP Diet
and Health Study was approved by the Special Studies Institutional
Review Board of the US National Cancer Institute.
As described earlier (Michaud et al, 2005), addresses for
members of the NIH-AARP cohort were updated annually by
matching the cohort database to that of the National Change of
Address database maintained by the US Postal Service. We
ascertained vital status by annual linkage of the cohort to the
Social Security Administration Death Master File, cancer registry
linkage, questionnaire responses, and responses to other mailings.
Incident cases of cancer through the year 2003 were identified by
probabilistic linkage between the NIH-AARP cohort membership
and the cancer registry databases of the states of residence at the
time of mailing the questionnaire with the addition of Arizona,
Nevada, and Texas, each of which has been certified by the North
American Association of Central Cancer Registries for meeting the
highest standards of data quality. For matching purposes, first and
last name, address history, gender, date of birth, and Social
Security number (available for 85% of our participants) were used.
We estimate the sensitivity of case identification to be about 90%.
Cancer sites were identified by anatomic site and histologic code as
detailed earlier (Freedman et al, 2007), using the International
Classification of Disease for Oncology, third edition. We classified
tumours with site codes C15.0–C15.9 as oesophageal cancers, site
code C16.0 as gastric cardia tumours, and site codes C16.1–C16.9
as non-cardia tumours. All included cancers were classified as
adenocarcinomas.
Our questionnaire assessed aspirin (generic aspirin and trade
names) use and non-aspirin NSAID use separately and the latter
named 19 non-aspirin NSAIDs (e.g., ibuprofen, sulindac etc., using
both generic and trade names) and specifically excluded Tylenol,
acetaminophen, and other pain relievers. Both questions asked
about any use in the past 12 months and asked users to mark how
frequently they took them: less than two times per month, two to
three times per month, one to two times per week, three to four
times per week, five to six times per week, one time per day, or two
or more times per day. Owing to small numbers in some of the
categories, we collapsed these into monthly, weekly, or daily use.
The baseline questionnaire contained questions about demo-
graphic information, cigarette use, alcohol consumption, education,
and a food frequency questionnaire of 124 items. Potential
confounders were categorised as described earlier (Abnet et al, 2008).
Statistics
We computed two-sided tests and considered P-values o0.05 or
estimates with confidence intervals (CIs) that excluded 1.0 as
statistically significant. To assess the potential for confounding, we
tabulated and compared known or potential risk factors by NSAID
use status. Hazard ratios (HRs) and 95% CIs were calculated using
Cox proportional hazards regression with follow-up time as the
underlying time metric using SAS 9.1 (Cary, NC, USA). All
presented estimates come from models adjusted for age at cohort
entry, sex, cigarette smoking status and intensity, alcohol use,
education, fruit intake, vegetable intake, BMI, total energy intake,
and both vigorous physical activity and usual physical activity
throughout the day. A small number of subjects were missing
values for some adjusting covariates and these subjects were
retained using dummy variables in the models. We modelled the
HR (95% CI) for any use of aspirin and of non-aspirin NSAIDs in a
single model (i.e., mutually adjusted models) and for frequency of
use with adjustment for the other category of NSAIDs. We tested
the proportional hazards assumption using cross-product terms
for interaction between follow-up time and any use of NSAIDs and
found no significant deviations from proportionality. Further-
more, we dropped 1, 2, or 3 years of initial follow-up and refitted
the models to assess lag effects and found none. Age-standardised
incidence rates were calculated as in Breslow and Day (1987) with
5-year age bands and age- and sex-specific rates standardised to
the entire NIH-AARP Diet and Health Study population.
Meta-analysis
To conduct the meta-analysis, we searched PubMed on 20
November 2008, with the following terms: (aspirin OR nsaid OR
nsaids OR non-steroidal) AND (gastric cancer OR oesophageal
cancer) AND (case-control OR cohort OR epidemiologic). We
reviewed the 128 retrieved abstracts to find relevant papers,
reading those in full in which the abstracts were not entirely
informative. We also reviewed earlier meta-analyses on aspirin and
NSAIDS in relation to oesophageal and gastric cancers (Corley
et al, 2003; Gonzalez-Perez et al, 2003; Wang et al, 2003) and other
review articles (Baron, 2003; Bosetti et al, 2003). We limited our
analysis to papers reporting case–control or cohort studies of the
association between the use of either aspirin or non-aspirin
NSAIDS and the risk of oesophageal or gastric adenocarcinomas.
We included the following studies for the oesophagus (Farrow
et al, 1998; Cheng et al, 2000; Lindblad et al, 2005; Anderson
et al, 2006; Jayaprakash et al, 2006; Ranka et al, 2006; Fortuny et al,
2007; Duan et al, 2008; Sadeghi et al, 2008), cardia (Farrow et al,
1998; Zaridze et al, 1999; Akre et al, 2001; Fortuny et al, 2007; Duan
et al, 2008; Sadeghi et al, 2008), non-cardia (Farrow et al, 1998;
Zaridze et al, 1999; Akre et al, 2001; Fortuny et al, 2007; Duan et al,
2008), and gastric NOS (Thun et al, 1993; Schreinemachers and
Everson, 1994; Coogan et al, 2000; Langman et al, 2000; Akre et al,
2001; Sorensen et al, 2003; Ratnasinghe et al, 2004; Lindblad et al,
2005) and excluded a few studies from certain sections that did not
specify the agent (Garidou et al, 1996; Suleiman et al, 2000) or the
histology of the oesophageal tumours (Funkhouser and Sharp,
1995; Langman et al, 2000). Two other studies, one prospective and
one retrospective, reported on the association between aspirin and
oesophageal adenocarcinoma, but included only subjects with
Barrett’s oesophagus in the reference group (Tsibouris et al, 2004;
Vaughan et al, 2005) and these papers are discussed separately.
From each selected paper, the effect measures (odds ratio (OR) or
HR) and 95% CIs were tabulated by two investigators. In each case,
we selected the most expansive measure of NSAID use and the
maximally adjusted model that did not include adjustment for
reflux symptoms (where possible). In some cases, we collapsed
multiple exposure groups into a single measure of association using
fixed effects models, and these are indicated by asterisks in the
figure. We used Stata/SE version 8.0 (Stat Corp., College Station,
TX, USA) and the meta and metabias commands to complete the
analyses. We report the results from random effects models, but the
results for fixed effects are similar in each case. Plots were created
using SigmaPlot 8.0 (Systat Corp., Chicago, IL, USA).
RESULTS
In the 12 months before baseline, 73% of the cohort had used
aspirin and 56% had used non-aspirin NSAIDs (Table 1), 25%
reported daily aspirin use and 10% reported daily non-aspirin
NSAID use. Aspirin users and non-aspirin NSAID users appeared
NSAIDs and upper GI adenocarcinomas
CC Abnet et al
552
British Journal of Cancer (2009) 100(3), 551–557 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ysimilar to each other and to the cohort as a whole in their age,
smoking histories, alcohol-drinking habits, education, diet, BMI,
and amount of physical activity.
The cohort members had an average of 6.7 years of follow-up
and we collected 2078248 person years of follow-up in total. The
HRs and 95% CIs for both any use and the frequency of aspirin or
non-aspirin NSAID use are given in Table 2. Models adjusted for
only age and sex produced similar results to these fully adjusted
models. For gastric non-cardia cancer, we found a strong dose-
dependent protective association for aspirin. Any aspirin use had
an HR (95% CI) of 0.64 (0.47–0.86). The HRs decreased from 0.74
for monthly use to 0.57 for weekly or daily use and the test for
trend across categories was significant (P¼0.0032). For non-
aspirin NSAIDs, any reported use showed a significantly decreased
risk of non-cardia gastric cancer, 0.68 (0.51–0.92). But there was
no clear trend; the HRs were 0.71, 0.48, and 0.82, for monthly,
weekly, and daily use, respectively, and the test for trend across
categories was borderline non-significant (P¼0.050). We saw no
significant associations between any use of aspirin (1.00, 0.73–
1.37) or non-aspirin NSAIDs (0.90, 0.69–1.17) and the risk of
oesophageal adenocarcinoma.
We combined aspirin and non-aspirin NSAIDs into a single
category and found statistically significantly reduced risk of non-
cardia gastric cancer, 0.64 (0.44–0.91), compared with never using
either agent, but no significant associations with risk of cancer at
the other two sites. As adenocarcinomas of the oesophagus and
cardia can be difficult to separate, we combined these two sites into
a single outcome, but still found no significant associations with
either aspirin or non-aspirin NSAID use. We adjusted for and also
stratified by reported use of antacids, a proxy marker for reflux
disease or heartburn, and found no differences compared with the
presented results (data not shown). We tested for and found no
evidence of a significant interaction between sex and NSAID use.
Finally, we deleted the first 1, 2, and 3 years of follow-up and found
similar results to those for the full follow-up period.
We calculated age-standardised incidence rates for non-cardia
gastric cancer in aspirin users and non-users. The rates (95% CI)
per 100000 person years dropped from 11.0 (8.4–13.6) in non-
aspirin users to 7.0 (5.7–8.3) in users. We also calculated rates
in men and women separately because of the underlying difference
in risk for this cancer. The number of non-cardia gastric cases in
women in our cohort was small (N¼53), and among aspirin non-
users and users we found rates of 6.4 (3.7–9.1) and 5.1 (3.3–6.9),
respectively. In men (N¼129), we found rates of 16.4 (11.6–21.1)
and 8.2 (6.4–9.9), respectively.
To put our results in a larger perspective, we completed a meta-
analysis of 49 risk estimates from 17 published studies reporting
the association between either aspirin (Figure 1A) or non-aspirin
NSAID (Figure 1B) use and the risk of oesophageal or gastric
adenocarcinoma. In the meta-analysis, aspirin use was inversely
associated with both gastric and oesophageal adenocarcinomas,
with summary ORs (95% CI) for non-cardia, cardia, and
oesophageal adenocarcinomas of 0.64 (0.52–0.80), 0.82 (0.65–
1.04), and 0.64 (0.52–0.79), respectively. The corresponding
Table 1 Distribution of covariates in NSAID users and non-users in NIH-AARP Diet and Health Study
Variable Cohort
Aspirin users in
the past 12 months
Non-aspirin NSAID
users in the past 12 months
Number 311115 (100%) 227198 (73%) 175591 (56%)
Age, years, mean (s.d.) 62.3 (5.3) 62.3 (5.3) 61.7 (5.4)
Sex, male, N (%) 180337 (58%) 141387 (62%) 97001 (55%)
Tobacco smoking
Never 111128 (37%) 79079 (36%) 61947 (36%)
Formero20 cigarettes per day, N (%) 84125 (28%) 61840 (28%) 48356 (28%)
FormerX20 cigarettes per day, N (%) 66306 (22%) 50395 (23%) 37966 (22%)
Currento20 cigarettes per day, N (%) 25506 (8%) 18088 (8%) 14150 (8%)
CurrentX20 cigarettes per day, N (%) 13924 (5%) 10323 (5%) 7505 (4%)
Education
High school or less, N (%) 72276 (24%) 49679 (22%) 38088 (22%)
Post-high school training, N (%) 103305 (34%) 75067 (34%) 58775 (34%)
College graduate, N (%) 61520 (20%) 46410 (21%) 35516 (21%)
Post-graduate education, N (%) 66493 (22%) 50702 (23%) 39087 (23%)
Alcohol, drinks per day, mean (s.d.) 0.9 (2.3) 1.0 (2.3) 0.9 (2.1)
Fruit intake, servings per day, mean (s.d.) 3.0 (2.4) 2.9 (2.3) 2.9 (2.3)
Vegetable intake, servings per day, mean (s.d.) 3.9 (2.4) 3.9 (2.4) 3.9 (2.4)
Body mass index, kgm
 2, mean (s.d.) 26.9 (5.0) 26.9 (4.8) 27.2 (5.1)
Vigorous physical activity
Never, N (%) 12309 (4%) 7619 (3%) 6154 (4%)
Rarely, N (%) 40323 (13%) 27952 (12%) 22580 (13%)
1–3 times per month, N (%) 41327 (13%) 30307 (13%) 24164 (14%)
1–2 times per week, N (%) 66624 (22%) 49501 (22%) 38486 (22%)
3–4 times per week, N (%) 85859 (28%) 64141 (28%) 49257 (28%)
X5 times per week, N (%) 62226 (20%) 46028 (20%) 33710 (20%)
Activity throughout the day
Sit during day, not much walking, N (%) 23614 (8%) 17063 (8%) 13887 (8%)
Sit much of the day, walk a fair amount, N (%) 74037 (33%) 74037 (33%) 58204 (34%)
Stand/walk a lot, no lifting, N (%) 118404 (39%) 86292 (39%) 65899 (38%)
Lift carry light loads, N (%) 54906 (18%) 40220 (18%) 30199 (18%)
Heavy work, N (%) 7874 (3%) 5670 (3%) 4331 (3%)
Abbreviation: NSAID¼non-steroidal anti-inflammatory drug.
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and 0.65 (0.50–0.85), respectively. Figure 2 shows a Begg funnel
plot for detecting publication bias in all the NSAID and upper GI
adenocarcinoma literature combined. The summary OR (95% CI)
for all estimates included in Figure 1A and B was 0.72 (0.67–0.79).
Using either the Begg test (P¼0.019) or the Egger test (P¼0.002),
we found evidence of publication bias and the figure suggests that
the current literature may overestimate the beneficial effects of
NSAIDs. But, when we excluded the smaller studies (those with
standard error greater than 0.2; N¼20) or those that showed
strong protection (log OR less than  0.50; N¼14), we found that
the association was essentially unchanged.
DISCUSSION
We found that reported use of aspirin or non-aspirin NSAIDs was
associated with a significant 36% reduction in the risk of non-
cardia gastric cancer consistent with the earlier studies. For ever
use of aspirin in the previous 12 months, age-adjusted rates of
gastric non-cardia cancer dropped from 11.0 in non-users to 7.0/
100000 person years in users. Although we did not find a
significant association between use of aspirin or other NSAIDs
with cardia cancer, the point estimate in our study was very close
to the summary estimate from the meta-analysis, which showed a
protective effect. Unlike most earlier observational studies, we
found no such association with oesophageal adenocarcinoma.
Our finding in the NIH-AARP cohort study that aspirin or other
NSAIDs had a protective association with gastric non-cardia
adenocarcinoma is consistent with the literature published earlier,
which is summarised in Figure 1. It appears that aspirin and non-
aspirin NSAIDs have similar effects, which may have implications
for cancer prevention. Eradication of Helicobacter pylori, the
strongest risk factor for gastric non-cardia adenocarcinoma, may
reduce its incidence (Talley, 2008). However, recent studies suggest
that H. pylori may have health benefits, such as preventing asthma
(Blaser et al, 2008) or oesophageal adenocarcinoma (Islami and
Kamangar, 2008). Beyond the direct benefits and risks of
eradication to the individual, the methods and consequences of
attempted widespread eradication, such as increasing antibiotic
resistance, must also be considered (Graham and Shiotani, 2008).
A single trial has tested the effect of the NSAID rofecoxib on
subjects with gastric pre-neoplastic lesions over 24 months and
found no evidence of benefit, but this study was small and did not
use cancer as an end point (Leung et al, 2006). The remarkably
consistent observational results showing that NSAID use is
associated with a reduced risk of gastric cancer may warrant a
randomised trial in a suitable population at high risk for the
disease in which side effects can be monitored closely.
The epidemiology of gastric cardia tumours in the United States
is similar to that of oesophageal adenocarcinoma. The incidence of
this tumour may have increased in recent years, but this change
may have occurred because of changing patterns of diagnosis or
because of the difficulty of separating adenocarcinomas in the
gastric cardia from those in the oesophagus (Kubo and Corley,
2002). We found no significant association between use of either
aspirin or non-aspirin NSAIDs and risk of gastric cardia
adenocarcinoma, but our point estimates are similar to the
summary estimates from our meta-analysis, which suggests a
significant protective effect.
We found no evidence that ever or daily aspirin use lowered the
risk of oesophageal adenocarcinoma, for which, as shown in
Figure 1, our results are discordant with many earlier studies. Most
of these showed some evidence, albeit not always significantly, that
use of aspirin or non-aspirin NSAIDs was associated with reduced
risk.
The reasons for these differences are not clear. Most earlier
studies had retrospective designs and may be prone to reverse
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ycausality for NSAIDs, as subjects with reflux symptoms, and
therefore at higher risk of oesophageal adenocarcinoma, may avoid
using NSAIDs producing the appearance of protection among
users. But at least one earlier prospective study found that NSAID
use reduced risk of progression to oesophageal adenocarcinoma
among subjects with Barrett’s oesophagus (Vaughan et al, 2005).
Recently, in the same cohort, the association is found strongest
among subjects with multiple molecular abnormalities that confer
the greatest risk of progressing to cancer, but absent in those at the
lowest risk (Galipeau et al, 2007). One study using subjects with
Barrett’s oesophagus as controls found that oesophageal adeno-
carcinoma cases and subjects with Barrett’s used aspirin and
NSAIDs at similar rates, but this differed with long-term reflux
symptoms (Tsibouris et al, 2004). One small, short-term trial
tested the effect of twice-daily treatment with 200mg of celecoxib
for 48 weeks on the proportion of dysplastic biopsies in subjects
with Barrett’s oesophagus and did not find any benefit (Heath et al,
2007). A large trial of proton pump inhibitors with or without
aspirin for the chemoprevention of oesophageal adenocarcinoma
in men with Barrett’s oesophagus is underway (Jankowski and
Moayyedi, 2004).
Our study has several strengths, being based on a large
prospective cohort that provided adequate power and minimised
recall bias, which may alter the associations found in case–control
studies. We used subject-completed questionnaires that captured
both over-the-counter and pharmacy-provided NSAIDs and
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Figure 2 Begg funnel plot with pseudo 95% confidence intervals
for all estimates included in the meta-analysis of NSAID use
and oesophageal or stomach adenocarcinoma. Both the Begg test
(P¼0.010) and the Egger test (P¼0.001) suggested publication bias,
but, dropping the studies with a standard error greater than 0.2 (N¼20) or
a log OR less than  0.50 (N¼14) left the association essentially
unchanged. Therefore, publication bias probably had little effect on the
summary estimates.
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yinformation on many potentially confounding exposures, many of
which (e.g., age, tobacco smoking, and physical activity) were
similar among NSAID users and non-users. On the other hand, we
captured only NSAID use over the previous 12 months and did not
collect the duration of use, which could have caused misclassifica-
tion of subjects who, for example, recently ceased NSAID use due
to upper gastrointestinal symptoms. But, we did adjust for and
stratify by antacid use without change in our risk estimates. We
could not assess infection with H. pylori and infected subjects may
have different patterns of NSAID use, which would lead to different
confounding effects in the stomach and oesophagus. Finally, this
study, being observational, is susceptible to confounding by other
unmeasured or poorly measured confounders, supporting the need
for randomised controlled trials.
In this large prospective cohort study, we found further evidence
that regular use of aspirin or non-aspirin NSAIDs may reduce the
risk of non-cardia gastric cancer; in contrast, this was not
associated with reduced risk of oesophageal adenocarcinoma,
thereby differing from most earlier studies.
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